SEC FIlings Archives - Page 7 of 19

09 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 9, 2023
Posted by Ulisses

09 Jan

SEC FIlings

Current Report

January 9, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 6, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 6, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Current Report

January 3, 2023
Posted by Jitendra

27 Dec

SEC FIlings

Notice of Effectiveness

January 3, 2023
Posted by Ulisses

27 Dec

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 3, 2023
Posted by Ulisses

20 Dec

SEC FIlings

Securities and Exchange Commission

December 21, 2022
Posted by Ulisses

09 Dec

SEC FIlings

Notice of Effectiveness

December 14, 2022
Posted by Jitendra

09 Dec

SEC FIlings

Prospectus [Rule 424(b)(3)]

December 12, 2022
Posted by Jitendra

SEC FIlings

Prospectus [Rule 424(b)(3)]

Current Report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current Report

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

Securities and Exchange Commission

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists